Summit Therapeutics Inc
SMMT19.680USD
+0.850+4.51%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
14.65BMarket Cap
LossP/E TTM
More Details of Summit Therapeutics Inc Company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Summit Therapeutics Inc Info
Ticker SymbolSMMT
Company nameSummit Therapeutics Inc
IPO dateOct 14, 2004
CEOZanganeh (Mahkam)
Number of employees159
Security typeOrdinary Share
Fiscal year-endOct 14
Address601 Brickell Key Drive
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33131
Phone13052032034
Websitehttps://www.smmttx.com/
Ticker SymbolSMMT
IPO dateOct 14, 2004
CEOZanganeh (Mahkam)
Company Executives of Summit Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
570.07M
+13980789.00%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+359730.00%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
570.07M
+13980789.00%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+359730.00%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Latin America
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Duggan (Robert William)
76.58%
Zanganeh (Mahkam)
4.80%
Baker Bros. Advisors LP
4.53%
Xia (Yu)
4.23%
The Vanguard Group, Inc.
1.53%
Other
8.33%
Shareholders
Shareholders
Proportion
Duggan (Robert William)
76.58%
Zanganeh (Mahkam)
4.80%
Baker Bros. Advisors LP
4.53%
Xia (Yu)
4.23%
The Vanguard Group, Inc.
1.53%
Other
8.33%
Shareholder Types
Shareholders
Proportion
Individual Investor
86.05%
Investment Advisor
5.94%
Hedge Fund
5.15%
Investment Advisor/Hedge Fund
2.50%
Research Firm
0.52%
Sovereign Wealth Fund
0.19%
Pension Fund
0.08%
Bank and Trust
0.01%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
517
107.30M
14.41%
-2.42M
2025Q3
489
101.69M
13.66%
-7.67M
2025Q2
447
727.40M
97.94%
-484.11K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Duggan (Robert William)
570.07M
76.58%
+13.98M
+2.51%
Oct 21, 2025
Zanganeh (Mahkam)
35.74M
4.8%
+359.73K
+1.02%
Apr 15, 2025
Baker Bros. Advisors LP
33.72M
4.53%
--
--
Sep 30, 2025
Xia (Yu)
31.52M
4.23%
--
--
Apr 15, 2025
The Vanguard Group, Inc.
11.38M
1.53%
+2.71M
+31.20%
Sep 30, 2025
Fidelity Management & Research Company LLC
8.92M
1.2%
-308.49K
-3.34%
Sep 30, 2025
State Street Investment Management (US)
6.36M
0.85%
+2.34M
+58.35%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.22M
0.84%
+303.11K
+5.12%
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.43M
0.59%
+627.20K
+16.50%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.13M
0.42%
+197.92K
+6.74%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
1.92%
State Street SPDR S&P Biotech ETF
1.57%
ProShares Ultra Nasdaq Biotechnology
1.38%
Invesco Nasdaq Biotechnology ETF
1.36%
First Trust Lunt US Factor Rotation ETF
0.99%
Direxion Daily S&P Biotech Bull 3X Shares
0.96%
Invesco NASDAQ Next Gen 100 ETF
0.77%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Pacer WealthShield ETF
0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.19%
View more
Tema Oncology ETF
Proportion1.92%
State Street SPDR S&P Biotech ETF
Proportion1.57%
ProShares Ultra Nasdaq Biotechnology
Proportion1.38%
Invesco Nasdaq Biotechnology ETF
Proportion1.36%
First Trust Lunt US Factor Rotation ETF
Proportion0.99%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.96%
Invesco NASDAQ Next Gen 100 ETF
Proportion0.77%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.64%
Pacer WealthShield ETF
Proportion0.25%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proportion0.19%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Summit Therapeutics Inc?
The top five shareholders of Summit Therapeutics Inc are:
Duggan (Robert William) holds 570.07M shares, accounting for 76.58% of the total shares.
Zanganeh (Mahkam) holds 35.74M shares, accounting for 4.80% of the total shares.
Baker Bros. Advisors LP holds 33.72M shares, accounting for 4.53% of the total shares.
Xia (Yu) holds 31.52M shares, accounting for 4.23% of the total shares.
The Vanguard Group, Inc. holds 11.38M shares, accounting for 1.53% of the total shares.
Duggan (Robert William) holds 570.07M shares, accounting for 76.58% of the total shares.
Zanganeh (Mahkam) holds 35.74M shares, accounting for 4.80% of the total shares.
Baker Bros. Advisors LP holds 33.72M shares, accounting for 4.53% of the total shares.
Xia (Yu) holds 31.52M shares, accounting for 4.23% of the total shares.
The Vanguard Group, Inc. holds 11.38M shares, accounting for 1.53% of the total shares.
What are the top three shareholder types of Summit Therapeutics Inc?
The top three shareholder types of Summit Therapeutics Inc are:
Duggan (Robert William)
Zanganeh (Mahkam)
Baker Bros. Advisors LP
Duggan (Robert William)
Zanganeh (Mahkam)
Baker Bros. Advisors LP
How many institutions hold shares of Summit Therapeutics Inc (SMMT)?
As of 2025Q4, 517 institutions hold shares of Summit Therapeutics Inc, with a combined market value of approximately 107.30M, accounting for 14.41% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.75%.
What is the biggest source of revenue for Summit Therapeutics Inc?
In FY2023, the -- business generated the highest revenue for Summit Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
